The timing of surgery in asymptomatic severe mitral regurgitation remains controversial. This observational study sought to compare long-term outcomes of early surgery with a conventional treatment strategy in asymptomatic patients with severe mitral regurgitation.

Stalking is one of the most common forms of interpersonal violence, with nearly 1 in 3 women experiencing it in their lifetime. Restraining orders are a legal remedy aimed at protecting women who experience the most severe forms of stalking and interpersonal violence. Previous work has shown associations between experiences of violence and cardiovascular health among women, but little is known about the link between being stalked or obtaining a restraining order and risk of cardiovascular disease (CVD).

Ultraprocessed foods and beverages (UPFs) pose a growing public health challenge. Commonly defined by the Nova system, UPFs are industrially processed products made with additives or ingredients not commonly used in home cooking. Although ultraprocessing or extensive processing can lower cost and improve shelf life, convenience, and taste of certain products, high UPF intake is consistently linked to negative health outcomes. Although mechanisms remain unclear, evidence supports food policies that limit UPF intake while avoiding unintended consequences. Identifying high-risk UPF subgroups is essential to balancing nutritional goals with the need for accessible and appealing food options. Most UPFs overlap with foods high in saturated fat, added sugars, and sodium, which are already targets for cardiometabolic risk reduction. Future priorities include uncovering how UPFs specifically affect cardiometabolic health, refining dietary guidance to discourage nutrient-poor UPFs, and clarifying the impact of UPFs with more favorable profiles. This science advisory reviews current evidence on UPFs and their impact on cardiometabolic health and outlines research needs, regulatory reform, and policy changes needed to affect better dietary intake and overall health.

GRKs (GPCR [G protein-coupled receptor] kinases) are key regulators of GPCR signaling. Because GPCRs are targeted by approximately 40% of clinical drugs, GRKs also represent therapeutic targets for combating cardiovascular diseases. However, the predominant GRK that responds to diabetic heart injury and the underlying mechanisms remain largely unknown.

Coronary artery calcium (CAC) is a strong predictor of cardiovascular outcomes, with patients having high CAC experiencing event rates similar to those in secondary prevention populations. Emerging evidence suggests that patients with extremely high CAC (≥1000) represent a distinct high-risk group. Therefore, this study aims to evaluate the prognostic value of myocardial flow reserve (MFR) in patients with very high CAC.

Assessment of left ventricular systolic function is essential for diagnosing and managing cardiac diseases and provides important prognostic information to the treating clinician. However, traditional methods for assessing left ventricular systolic function such as ejection fraction are limited by their reliance on geometric assumptions, subjective reader interpretation, sensitivity to loading conditions and volume, and reflection of a single plane of motion. In addition to interobserver and intraobserver variability and technical confounders, this evaluation is complicated by the complex 3-dimensional organization of the myocardial fibers, which are oriented longitudinally in the subendocardium, transversely in the midmyocardium, and obliquely in the subepicardium. Conversely, 2-dimensional speckle-tracking echocardiography measures left ventricular deformation as myocardial strain in the 3 planes of chamber motion: longitudinal, circumferential, and radial. From a clinical perspective, left ventricular global longitudinal strain offers superior diagnostic and prognostic value across the spectrum of cardiovascular disorders compared with ejection fraction, is highly reproducible, and detects subclinical dysfunction before the ejection fraction declines. Given the expanding clinical utility of speckle-tracking echocardiography and the incremental prognostic and therapeutic value of integrating global longitudinal strain into clinical practice as a potential biomarker, the objectives of this scientific statement are (1) to review the principles and technical aspects of speckle-tracking echocardiography strain imaging; (2) to provide a practical, evidence-based review of the application of speckle-tracking echocardiography in heart failure, cardiomyopathies, ischemic heart disease, valvular disease, and cardio-oncology; (3) to explore the potential utility of speckle-tracking echocardiography in cardiac resynchronization and implantable cardioverter defibrillator therapy; and (4) to outline the future directions of speckle-tracking echocardiography.

Abdominal aortic aneurysm (AAA) is a life-threatening vascular disease with no effective pharmacological treatments. The causal role of triglycerides (TGs) in AAA development remains unclear and controversial.

Acute myocarditis (AM), particularly fulminant myocarditis (FM), is an infrequent but life-threatening cardiac inflammation, with limited effective precision-targeted treatments available. This urgent clinical challenge has prompted further investigations into the mechanisms underlying this pathology to develop novel therapeutic approaches.

Outcome reporting in cardio-obstetrics studies is inconsistent. The objective of the COSCarP study (Core Outcome Set on Cardiac Diseases in Pregnancy) was to develop a core outcome set through international consensus and harmonize outcome reporting in cardio-obstetrics studies.

Imatinib, the first Abl-tyrosine kinase inhibitor (TKI), improved leukemia outcomes without cardiovascular side effects. Newer agents, including ponatinib, addressed imatinib resistance, improving cancer remission, but substantially increased arterial thrombotic events, including myocardial infarction (MI) and stroke. The mechanism behind ponatinib-induced thrombosis and the cardiovascular effect of asciminib, a newly approved Abl-TKI, remain unknown.